Matthew Barcus
Stock Analyst at Chardan Capital
(2.30)
# 2,233
Out of 5,178 analysts
21
Total ratings
21.74%
Success rate
21.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $6.04 | +65.56% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $15.60 | +73.08% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $98 | $8.68 | +1,029.03% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $25.36 | +26.18% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $2,200 | $3.99 | +55,037.84% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $2.63 | +242.21% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $20.41 | -60.80% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $6.04
Upside: +65.56%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $15.60
Upside: +73.08%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $98
Current: $8.68
Upside: +1,029.03%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $25.36
Upside: +26.18%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $2,200
Current: $3.99
Upside: +55,037.84%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $2.63
Upside: +242.21%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $20.41
Upside: -60.80%